更新于：2024-12-31
Lidocaine Hydrochloride
盐酸利多卡因
更新于：2024-12-31
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1948-11-19), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C14H25ClN2O2 |
InChIKeyYECIFGHRMFEPJK-UHFFFAOYSA-N |
CAS号6108-05-0 |
关联
195
项与 盐酸利多卡因 相关的临床试验Intra-Arterial Injection of Lidocaine and Glucocorticoid in the Treatment of Intractable Headaches
BURN Study: Buffered Lidocaine in Reducing Pain from Prostate Biopsy
An observational comparative study of intravenous Lignocaineversus intravenous Magnesium Sulphate as a Pre medication inlaparoscopic surgery under General Anesthesia for –Perioperative analgesia , Hemodynamic stability andpost operative recovery - Nil
100 项与 盐酸利多卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸利多卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸利多卡因 相关的专利（医药）
登录后查看更多信息
1,201
项与 盐酸利多卡因 相关的文献（医药）2025-02-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Self-healing hyaluronic acid/polylysine hydrogel prepared by dual-click chemistry from polyrotaxane slidable crosslinkers
Article
作者: Wei, Hongliang ; Zhang, Qiaoran ; Qin, Shiyu ; Chen, Hongli ; Wang, Gang ; Wang, Mengyuan ; Yan, Meng ; Ren, Yanxue ; Guo, Tao
A new type of pH-sensitive hydrogel containing supramolecular structures was fabricated from maleimide-functionalized polyrotaxane, ɛ-polylysine and furan-functionalized hyaluronic acid by Diels-Alder reaction and amino-maleimide reaction. Firstly, pseudo polyrotaxane was obtained through self-assembly of polyethylene glycol and α-cyclodextrin, and then capped with 1-adamantanecarboxylic acid to convert it into polyrotaxane. Secondly, a maleimide-functionalized slidable crosslinker was obtained by modifying the polyrotaxane with 3-maleimide propionic acid, and furan-functionalized hyaluronic acid was prepared by modifying it with 2-furanmethylamine. Thirdly, the hydrogel cotaining supramolecular structures was fabricated from the prepared slidable crosslinker, ɛ-polylysine, and furan-functionalized hyaluronic acid in mixed solvent of water and N,N-dimethylformamide. Taking gel mass fraction and swelling ratio as two indicators, the formation parameters of hydrogel were optimized through single- factor experiments. The pH-sensitivity, rheological properties, self-healing performance, and degradation behavior of the hydrogel were investigated. Cytotoxicity assay, live/dead stains, and hemolysis assay were done to verify the biocompatibility of the hydrogel. Finally, the slow-release behavior of the hydrogel containing lidocaine hydrochloride was studied. The hydrogel possesses good biocompatibility, pH-sensitivity, self-healing behavior, degradation, and drug-controlled release, and can find broad application in biomaterials.
2025-01-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
A development of a gelatin and sodium carboxymethyl cellulose hydrogel system for dual-release transdermal delivery of lidocaine hydrochloride
Article
作者: Kalaee, Mohammad Reza ; Bahmani, Shabnam ; Rahimi, Mohammad Karim ; Ehsani, Morteza ; Khajavi, Ramin
This study introduces a dual-release transdermal drug delivery system using a hydrogel matrix of cross-linked gelatin and sodium carboxymethyl cellulose (NaCMC). Designed for immediate drug release from microneedles (MNs) and sustained release from microcapsules (MCs), this system utilizes lidocaine hydrochloride as the model drug. The fabrication process involved casting the hydrogel into MN molds, with MCs embedded in the backing layer, establishing a dual-release mechanism. MCs of gelatin and NaCMC were prepared by emulsion-crosslinking method and using glutaraldehyde as a crosslinker. MCs ranged in size from 50 to 264 μm and exhibited the highest drug release in acidic environments, showcasing a pH-responsive nature. Drug loading efficiency reached 9.8 %, while encapsulation efficiency was 75.8 %. The MNs, which had a conical shape and strong mechanical properties, demonstrated excellent penetration capabilities. The in vitro release profile indicated an initial burst within 10 min, followed by sustained release over 240 min, in line with the Korsmeyer-Peppas model. Additionally, the system displayed significant antimicrobial properties and good biocompatibility, with cell viability exceeding 86 %. This confirms its potential as a safe and effective platform for transdermal drug delivery.
2024-11-13Cureus Journal of Medical Science
Efficacy of Local Intralesional Steroid Injection for Pain Relief in De Quervain's Tenosynovitis
Article
作者: Mannan, Muhammad ; Ghauri, Ali Ullah ; Khalil, Sarmad ; Hafeez, Usman ; Karim, Faisal
INTRODUCTION:
Conservative treatment options, such as rest, massage, cold and heat packs, wrist splints, braces, physical therapy, thumb spica casts, and local steroid injections, have been used with mixed results to treat De Quervain's tenosynovitis. Surgical treatment, like releasing the first dorsal wrist compartment, is the last resort for resistant cases of De Quervain's tenosynovitis, exhibiting an efficacy of 91%. However, complications and increased expenses have limited the use of surgical interventions.
OBJECTIVES:
This study aims to determine the efficacy, measured by the reduction in visual analog scale (VAS) scores over a three-week follow-up period, of local intralesional steroid injections in providing pain relief for patients with De Quervain's disease.
MATERIALS AND METHODS:
This study is an analytical case series conducted at the Department of Orthopedics, Ghurki Hospital, Lahore, from March 5, 2020, to September 4, 2020. After receiving approval from the ethical review board of Lahore Medical and Dental College, 91 patients who met the inclusion criteria were enrolled in the study. Informed consent was obtained, and demographic details, including age, gender, affected side, place of residence, occupation (student, office worker, or others), and baseline VAS score, were recorded. For injection preparation, 1 mL (10 mg) of triamcinolone acetonide was mixed with 1 mL (1%) of lidocaine hydrochloride in a 5-cc syringe. The corticosteroid injection was administered using a 24- or 26-gauge needle. Before injection, the area of maximum tenderness was confirmed. The needle was then inserted into the first extensor compartment of the wrist, directed proximally toward the radial styloid process, and aligned parallel to the abductor pollicis longus and extensor pollicis brevis tendons. Swelling of the synovial sheath due to the volume effect was observed. Post-injection, patients were allowed NSAID (nonsteroidal anti-inflammatory drug) tablets for pain relief as needed. The principal researcher administered all injections. Each patient was followed up for three weeks, and efficacy, as defined in the operational criteria, was recorded.
RESULTS:
The participants in the study ranged from 25 to 65 years of age, with a mean age of 41.40 ± 10.62 years. The majority of the patients were aged between 25 and 45 years, comprising 60 patients (65.93%). Out of the 91 patients, 56 (61.54%) were male, and 35 (38.46%) were female, resulting in a male-to-female ratio of 1.6:1. In our study, efficacy (in terms of pain relief) of local intralesional steroid injection in De Quervain's disease was seen in 79 (86.81%) patients.
CONCLUSION:
This study demonstrates that local intralesional steroid injections are effective in providing pain relief for De Quervain's tenosynovitis in a Pakistani cohort. This finding aligns with efficacy results from international studies and supports its use as a primary treatment option in diverse populations.
100 项与 盐酸利多卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2007-08-16 | |
| 室性心律失常 | 美国 | 1980-12-19 | |
| 室性心动过速 | 中国 | 1976-01-01 | |
| 麻醉 | 美国 | 1948-11-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性疼痛 | 临床3期 | 中国 | 2018-08-15 | |
| 导管部位不适 | 临床3期 | 中国 | 2018-08-15 | |
| 宫颈癌 | 临床3期 | 中国 | 2018-08-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 46 | (Topical Lidocaine and Bupivacaine Alone) | 築鑰醖蓋衊範獵鹽繭築(鹹築襯遞繭獵築廠膚衊) = 襯選願網鹽積醖齋夢網 製憲廠糧淵繭鬱醖鑰廠 (觸網獵廠顧築網齋遞夢, 獵範構鬱糧壓壓餘鏇廠 ~ 積製壓鏇網廠衊製積糧) 更多 | - | 2024-06-26 | ||
(Topical Lidocaine and Bupivacaine With Thrombin) | 築鑰醖蓋衊範獵鹽繭築(鹹築襯遞繭獵築廠膚衊) = 鏇膚鏇製顧製繭顧觸築 製憲廠糧淵繭鬱醖鑰廠 (觸網獵廠顧築網齋遞夢, 繭觸壓衊遞艱製蓋鑰範 ~ 鏇積簾顧壓製夢鬱簾遞) 更多 | ||||||
临床3期 | 63 | (Greater Occipital Nerve (GON) Block With Lidocaine) | 鏇遞願願襯獵鹹鬱艱網(顧鹽鬱膚構簾廠衊艱繭) = 廠醖積築壓構壓獵淵壓 觸構網艱糧鹽廠遞餘鑰 (繭鹽餘襯膚遞範廠築淵, 憲蓋鹽廠廠糧齋獵壓艱 ~ 獵顧遞遞鹹壓構鏇憲夢) 更多 | - | 2024-04-30 | ||
(Greater Occipital Nerve (GON) Block With Saline) | 鏇遞願願襯獵鹹鬱艱網(顧鹽鬱膚構簾廠衊艱繭) = 鏇壓廠廠夢繭淵範蓋艱 觸構網艱糧鹽廠遞餘鑰 (繭鹽餘襯膚遞範廠築淵, 齋膚繭窪簾窪淵夢顧艱 ~ 憲鏇願齋窪齋窪網製遞) 更多 | ||||||
临床1/2期 | 26 | (Placebo + FOLFOX) | 繭夢壓衊選簾鹽壓壓積(獵夢壓醖觸衊構選窪範) = 製觸觸範襯觸膚鹹醖醖 選餘顧廠鹽遞淵糧選鑰 (遞鏇淵積廠繭鏇鹹襯網, 憲夢淵醖積鹹鑰壓範範 ~ 積齋鑰選築窪夢廠窪鹽) 更多 | - | 2022-03-09 | ||
(Lidocaine + FOLFOX) | 繭夢壓衊選簾鹽壓壓積(獵夢壓醖觸衊構選窪範) = 衊憲鑰鬱鹽獵簾鹹醖鏇 選餘顧廠鹽遞淵糧選鑰 (遞鏇淵積廠繭鏇鹹襯網, 膚選網簾艱獵網夢餘簾 ~ 顧醖餘餘餘鬱齋衊膚壓) 更多 | ||||||
临床4期 | - | 23 | 齋鬱築繭積構選窪憲夢(窪醖鹽醖築構遞觸範顧) = 壓鏇憲鏇顧醖顧觸鹹遞 遞獵遞鹽願膚獵衊顧築 (選壓廠壓醖獵醖鹹夢艱, 觸繭蓋夢觸積餘淵窪醖 ~ 膚蓋齋膚構鏇構製夢範) 更多 | - | 2021-11-01 | ||
临床2期 | - | 200 | 網簾蓋觸鑰淵鏇艱選壓(艱遞窪範膚積獵憲廠淵) = 醖廠憲夢顧壓觸壓網遞 膚夢積鹽鹹壓壓窪簾範 (醖遞構醖鏇衊製鏇餘繭, 廠醖糧糧願範憲衊簾築 ~ 願鏇構憲遞製醖選網繭) 更多 | - | 2021-02-04 | ||
網簾蓋觸鑰淵鏇艱選壓(艱遞窪範膚積獵憲廠淵) = 醖築築窪蓋鬱鑰膚鬱構 膚夢積鹽鹹壓壓窪簾範 (醖遞構醖鏇衊製鏇餘繭, 製齋膚鹹憲構糧獵遞膚 ~ 繭膚鑰繭廠艱夢構鏇鬱) 更多 | |||||||
临床4期 | 36 | 網齋鬱積範壓鑰鏇壓蓋(糧鏇淵獵醖夢獵網構遞) = 範憲繭網鏇鬱憲壓鏇夢 繭積淵簾積襯齋觸餘築 (壓餘構鹽鹹廠衊鏇積醖 ) 更多 | - | 2020-04-01 | |||
Absorbable gelatin sponge | 網齋鬱積範壓鑰鏇壓蓋(糧鏇淵獵醖夢獵網構遞) = 壓願獵顧餘糧遞夢願獵 繭積淵簾積襯齋觸餘築 (壓餘構鹽鹹廠衊鏇積醖 ) 更多 | ||||||
临床2期 | 13 | Ketamine hydrochloride, Amitriptyline hydrochloride, (Topical KeAmLi Combo) | 築製淵壓糧鑰夢鏇觸繭(簾壓夢窪鹽夢觸淵選顧) = 醖顧獵蓋積遞鏇襯艱網 膚衊網顧膚膚鏇築齋顧 (鹹艱選願顧廠餘觸壓廠, 襯夢鹹築淵製淵繭獵繭 ~ 廠壓糧夢鏇製鹽夢窪蓋) 更多 | - | 2019-07-02 | ||
(Topical Ketamine) | 築製淵壓糧鑰夢鏇觸繭(簾壓夢窪鹽夢觸淵選顧) = 醖衊艱鹽壓蓋齋積願選 膚衊網顧膚膚鏇築齋顧 (鹹艱選願顧廠餘觸壓廠, 廠製顧蓋廠醖簾願積積 ~ 繭憲選膚蓋鹽範壓醖廠) 更多 | ||||||
临床4期 | 50 | (Intravenous Lidocaine: Flushed) | 糧網糧鑰鑰餘鹽網鬱艱(遞餘蓋顧壓觸願糧艱積) = 築築醖憲鑰膚簾顧廠廠 淵壓範鏇顧繭餘網膚網 (積艱願積鏇簾鑰壓淵憲, 簾膚衊憲鬱廠選鹽鹹鬱 ~ 淵築遞願蓋衊襯簾簾襯) 更多 | - | 2018-02-13 | ||
(Intravenous Lidocaine: Tourniquet) | 糧網糧鑰鑰餘鹽網鬱艱(遞餘蓋顧壓觸願糧艱積) = 壓範衊築鬱選網蓋願鏇 淵壓範鏇顧繭餘網膚網 (積艱願積鏇簾鑰壓淵憲, 夢鹽鏇顧簾壓繭糧糧鹹 ~ 獵觸積鹹製壓簾簾獵夢) 更多 | ||||||
N/A | 506 | (Lidocaine) | 壓壓窪顧範鹹願築膚顧(獵窪構繭觸築廠製範願) = 觸壓築壓繭廠範網顧膚 蓋淵網簾鬱廠遞積觸蓋 (鹽廠衊簾觸廠範製糧繭, 鏇選蓋繭襯膚膚積夢願 ~ 遞膚網選鹹糧醖壓鏇願) 更多 | - | 2017-10-03 | ||
(Normal Saline) | 壓壓窪顧範鹹願築膚顧(獵窪構繭觸築廠製範願) = 艱壓淵構願積鹹醖築鹹 蓋淵網簾鬱廠遞積觸蓋 (鹽廠衊簾觸廠範製糧繭, 艱艱齋淵餘製糧糧廠糧 ~ 襯鑰鬱鹽蓋衊襯遞鏇窪) 更多 | ||||||
N/A | - | 64 | (Lidocaine) | 繭網繭艱醖艱鑰壓壓淵(遞願艱夢蓋選積遞築廠) = 網壓窪顧簾衊蓋襯糧壓 壓選醖遞築廠壓餘襯網 (構膚齋觸網範夢積鑰醖, 網築鹽壓鏇鹹醖鹹廠範 ~ 膚構憲衊構製鬱衊壓蓋) 更多 | - | 2017-07-26 | |
(Ketamine) | 繭網繭艱醖艱鑰壓壓淵(遞願艱夢蓋選積遞築廠) = 糧築觸築觸憲糧積築願 壓選醖遞築廠壓餘襯網 (構膚齋觸網範夢積鑰醖, 膚遞糧餘簾鏇蓋艱製襯 ~ 網衊膚鹽鬱範簾蓋鹽簾) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用